A Next-Generation Treatment for Familial Hypercholesterolaemia
Time: 1:30 pm
day: Day One
Details:
- Exploring a novel CRISPR-based gene editing approach to upregulate LDLR expression
- Outlining the potential efficacy, safety and dosing benefits of avoiding PCSK9 knockouts
- Explaining the benefits of proprietary novel nucleases for this treatment option
